Financials Nightingale Health Oyj
Equities
HEALTH
FI4000490875
Advanced Medical Equipment & Technology
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.785 EUR | +4.08% | +6.25% | +59.95% |
04-16 | Finland’s Nightingale Health Plots US Expansion | MT |
04-16 | Nightingale Health to Establish A Laboratory in the United States | CI |
Valuation
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 345.9 | 108.9 | 52.44 | 103.5 | - | - |
Enterprise Value (EV) 1 | 237.2 | 16.83 | -26.93 | 37.58 | 51.28 | 103.5 |
P/E ratio | -21.4 x | -6.95 x | -2.9 x | -6.35 x | -6.35 x | -9.03 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 166 x | 49.4 x | 12.5 x | 22 x | 11.9 x | 6.85 x |
EV / Revenue | 114 x | 7.63 x | -6.44 x | 8 x | 5.89 x | 6.85 x |
EV / EBITDA | -49.9 x | -2.14 x | 2.28 x | -3.84 x | -5.34 x | -16.2 x |
EV / FCF | -42.5 x | - | 2.29 x | -2.76 x | -3.51 x | -7.78 x |
FCF Yield | -2.35% | - | 43.6% | -36.2% | -28.5% | -12.9% |
Price to Book | 2.77 x | 0.99 x | 0.53 x | 1.29 x | 1.62 x | - |
Nbr of stocks (in thousands) | 59,952 | 60,304 | 60,341 | 60,341 | - | - |
Reference price 2 | 5.770 | 1.806 | 0.8690 | 1.715 | 1.715 | 1.715 |
Announcement Date | 21-09-15 | 22-09-29 | 23-09-28 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | 2.081 | 2.205 | 4.182 | 4.7 | 8.7 | 15.1 |
EBITDA 1 | -4.752 | -7.846 | -11.84 | -9.8 | -9.6 | -6.4 |
EBIT 1 | -5.222 | -11.08 | -18.52 | -17.8 | -17.6 | -13.1 |
Operating Margin | -250.94% | -502.72% | -442.95% | -378.72% | -202.3% | -86.75% |
Earnings before Tax (EBT) 1 | - | -15.42 | -18.07 | -16.3 | -16.7 | -12.4 |
Net income 1 | - | -15.38 | - | -16.4 | -16.7 | -11.8 |
Net margin | - | -697.32% | - | -348.94% | -191.95% | -78.15% |
EPS 2 | -0.2700 | -0.2600 | -0.3000 | -0.2700 | -0.2700 | -0.1900 |
Free Cash Flow 1 | -5.582 | - | -11.74 | -13.6 | -14.6 | -13.3 |
FCF margin | -268.24% | - | -280.8% | -289.36% | -167.82% | -88.08% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 21-09-15 | 22-09-29 | 23-09-28 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 1.013 | 1.068 | 1.322 | 0.884 | 2.243 | 1.939 | 1.715 | 3 |
EBITDA 1 | - | -2.601 | -3.254 | -4.592 | -5.463 | -6.372 | -5.336 | -4.5 |
EBIT 1 | - | -2.883 | -4.78 | -6.305 | -8.672 | -9.852 | -9.306 | -8.5 |
Operating Margin | - | -269.94% | -361.57% | -713.24% | -386.63% | -508.1% | -542.62% | -283.33% |
Earnings before Tax (EBT) 1 | - | - | -5.062 | -10.36 | -8.547 | - | -8.502 | -7.8 |
Net income 1 | -3.005 | - | -5.063 | - | -8.553 | - | -8.529 | -7.8 |
Net margin | -296.64% | - | -382.98% | - | -381.32% | - | -497.32% | -260% |
EPS 2 | - | - | -0.0900 | -0.1700 | -0.1400 | -0.1600 | -0.1400 | -0.1300 |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 21-03-15 | 21-09-15 | 22-02-24 | 22-09-29 | 23-03-23 | 23-09-28 | 24-03-07 | - |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 109 | 92.1 | 79.4 | 65.9 | 52.2 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -5.58 | - | -11.7 | -13.6 | -14.6 | -13.3 |
ROE (net income / shareholders' equity) | -16.8% | -13.1% | -17.3% | -18.4% | -23% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share 2 | 2.080 | 1.820 | 1.630 | 1.330 | 1.060 | - |
Cash Flow per Share 2 | -0.0700 | - | -0.1400 | -0.1600 | -0.1700 | - |
Capex 1 | 4.73 | - | 4.41 | 3.7 | 4 | 4.5 |
Capex / Sales | 227.44% | - | 105.55% | 78.72% | 45.98% | 29.8% |
Announcement Date | 21-09-15 | 22-09-29 | 23-09-28 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.95% | 111M | |
+4.63% | 32.55B | |
+18.46% | 7.66B | |
+21.38% | 3.85B | |
-17.01% | 3.14B | |
-22.16% | 1.35B | |
-31.01% | 1.18B | |
+4.40% | 934M | |
-34.81% | 911M | |
-25.64% | 840M |
- Stock Market
- Equities
- HEALTH Stock
- Financials Nightingale Health Oyj